AUTHORS
Steven Holden, MLS(ASCP)CM, SBB(ASCP)CM, Marcus Geer, MD2, Jennifer Marie Jones, MD3
AFFILIATIONS
1 University of Michigan, Ann Arbor, Michigan, United States
2 University of Michigan, Ann Arbor, Michigan, United States
3 University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States
ABSTRACT
Background
Pure red cell aplasia (PRCA) is a well-described adverse effect of ABO-incompatible hematopoietic stem cell transplantation (HSCT) with an incidence of approximately 5 to 12% (Aung FM, et al., 2014). Among proposed risk factors for transplant-associated PRCA, elevated pre-transplant IgG isohemagglutinin titers are biologically compelling. Persistently elevated anti-A and/or -B titers may target corresponding antigens expressed by donor red blood cell (RBC) precursors, leading to erythroid aplasia, prolonged transfusion dependence, and iron overload. In this single-center retrospective study, we sought to evaluate the relationship between pre-transplant IgG isohemagglutinin titers and incidence of PRCA in ABO-incompatible HSCT recipients.
Methods
We performed a retrospective review of PRCA incidence among ABO-incompatible HSCT recipients at a single center from 2019 to 2025. Study subjects were identified from in-house cellular therapy records. Adult recipients of a major or bidirectional ABO-incompatible HSCT with at least one measured pre-transplant isohemagglutinin titer were eligible for inclusion. Variables collected included basic demographic information, pre-transplant isohemagglutinin titer values, graft characteristics, conditioning and graft-versus-host-disease (GVHD) regimens, GVHD incidence, and post-transplant RBC units transfused prior to RBC engraftment (defined as the first of 30 consecutive days without requiring an RBC transfusion). We used univariate and multivariate logistic regression to evaluate the relationship between pre-transplant isohemagglutinin titers and incidence of PRCA. Subsequently, we used survival analysis and negative binomial regression to investigate associations with delayed RBC engraftment and transfusion burden. Statistical analysis was performed in Stata BE Version 18.5.
Results
Seventy-four unique subjects underwent 78 major or bidirectional ABO-incompatible HSCTs during the study period. The median age of the cohort was 61 years (IQR 46 to 67) and 54% were male. Bone marrow grafts were used for four HSCTs (5%). Peripheral blood stem cells were used for all others. Myeloablative conditioning was more common than reduced intensity and nonmyeloablative regimens (58% vs. 42%), and the most frequently used immunosuppressive combinations for GVHD prophylaxis were tacrolimus/methotrexate (65%) and tacrolimus/mycophenolate mofetil/post-transplant cyclophosphamide (PTCy, 20%). The median pre-transplant IgG titer was 128 (IQR: 32 to 512). No subjects received pre-transplant desensitization for elevated isohemagglutinin titers, though all marrow grafts were RBC-reduced prior to infusion.
PRCA developed following seven HSCTs (9%). In a penalized logistic regression, pre-transplant IgG titer values were associated with PRCA after adjustment for age and conditioning regimen (OR 2.38, 95%CI 1.23 – 4.60, p = 0.010). No other covariates altered the association between pre-transplant IgG titer and PRCA.
In survival analysis, higher pre-transplant IgG titers were also associated with longer RBC engraftment times (HR 0.75, 95% CI 0.67 to 0.85, p < 0.001). Specifically, subjects with pre-transplant titers ≥ 128 experienced longer RBC engraftment times compared to those with titers < 128 (Median: 25 days, IQR 14 to 75 vs. 15 days, IQR 12 to 24, p = 0.02). Notably, GVHD prophylaxis regimens containing PTCy were also associated with longer RBC engraftment times (Median: 56 days, IQR 24 to 93 vs.15 days, IQR 13 to 29, p = 0.01; HR 0.49, 95% CI 0.264 to 0.91, p = 0.02). Subjects with pre-transplant IgG titers ≥ 128 required more post-transplant RBC transfusions (Median: 6 units, IQR 4 to 21 vs. 3 units, IQR 0 to 6, p= 0.01). For each doubling of pre-transplant IgG titer, subjects required 28% more post-transplant RBC transfusions (IRR 1.27, 95% CI 1.16 – 1.40, p < 0.001).
Conclusion
In this retrospective evaluation of ABO-incompatible HSCT recipients, subjects with elevated pre-transplant isohemagglutinin IgG titers, especially those with ≥ 128, experienced increased incidence of post-transplant PRCA, delayed RBC engraftment, and increased transfusion burden. Effective desensitization strategies for pre-transplant IgG isohemagglutinin have not been established. However, future trials could consider addition of therapies targeting humoral immunity to conditioning regimens in ABO-incompatible HSCT candidates identified with high pre-transplant isohemagglutinin titers.
DISCLOSURES
Jennifer Marie Jones, MD: No relevant conflicts of interest to declare.